PT - JOURNAL ARTICLE AU - Ma, Jiantao AU - Joehanes, Roby AU - Liu, Chunyu AU - Keshawarz, Amena AU - Shih-Jen, Hwang AU - Bui, Helena AU - Tejada, Brandon AU - Sooda, Meera AU - Munson, Peter J. AU - Cumhur, Demirkale Y. AU - Courchesne, Paul AU - Heard-Costa, Nancy L. AU - Pitsillides, Achilleas N. AU - Feolo, Mike AU - Sharopova, Nataliya AU - Vasan, Ramachandran S. AU - Huan, Tianxiao AU - Levy, Daniel TI - Elucidating the genetic architecture of DNA methylation to identify promising molecular mechanisms of disease AID - 10.1101/2022.04.13.22273848 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.13.22273848 4099 - http://medrxiv.org/content/early/2022/05/16/2022.04.13.22273848.short 4100 - http://medrxiv.org/content/early/2022/05/16/2022.04.13.22273848.full AB - DNA methylation commonly occurs at cytosine-phosphate-guanine sites (CpGs) that can serve as biomarkers for many diseases. We analyzed whole genome sequencing data to identify DNA methylation quantitative trait loci (mQTLs) in 4,126 Framingham Heart Study participants. Our mQTL mapping identified 94,362,817 cis-mQTLvariant-CpG pairs (for 210,156 unique autosomal CpGs) at P<1e-7 and 33,572,145 trans-mQTL variant-CpG pairs (for 213,606 unique autosomal CpGs) at P<1e-14. Using cis-mQTL variants for 1,258 CpGs associated with seven cardiovascular disease risk factors, we found 104 unique CpGs that colocalized with at least one cardiovascular disease trait. For example, cg11554650 (PPP1R18) colocalized with type 2 diabetes, driven by a single nucleotide polymorphism (rs2516396). We performed Mendelian randomization (MR) analysis and demonstrated 58 putatively causal relations of CVD risk factor-associated CpGs to one or more risk factors (e.g., cg05337441 [APOB] with LDL; MR P=1.2e-99, and 17 causal associations with coronary artery disease (e.g. cg08129017 [SREBF1] with coronary artery disease; MR P=5e-13). We also showed that three CpGs, e.g., cg14893161 (PM20D1), are putatively causally associated with COVID-19 severity. To assist in future analyses of the role of DNA methylation in disease pathogenesis, we have posted a comprehensive summary data set in the National Heart, Lung, and Blood Institute’s BioData Catalyst.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Framingham Heart Study was supported by NIH contracts N01-HC-25195, HHSN268201500001I, and 75N92019D00031.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board for Human Research at Boston University Medical CenterI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at dbGap https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000974.v4.p3